Crinone

Amenorrhea, hormonal imbalance, prophylaxis of recurrent spontaneous preterm birth + 9 more

Treatment

20 Active Studies for Crinone

What is Crinone

Progesterone

The Generic name of this drug

Treatment Summary

Progesterone is a naturally-occurring hormone in women that helps with fertility and pregnancy. Low levels of progesterone or a lack of a response to progesterone can lead to infertility or pregnancy loss. Progesterone is also used in various contraceptive preparations to stop ovulation and fertilization. It is available in different forms, such as capsules, gel, tablets, inserts, and injections. Progesterone can be made from plants and is chemically identical to the progesterone found in the human body.

Progesterone

is the brand name

image of different drug pills on a surface

Crinone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Progesterone

Progesterone

1978

124

Effectiveness

How Crinone Affects Patients

Progesterone has many different effects, depending on the concentration and delivery form of the drug. Generally, it helps to transition the uterus from the growth phase to the preparation phase needed for pregnancy. It also helps to provide a supportive environment for a fertilized egg and maintain a pregnancy. Progesterone can also be used as a contraceptive, as it suppresses ovulation, thickens cervical mucus to prevent sperm movement, and lowers the levels of hormones that trigger ovulation. Injections of progesterone are used to help prevent overgrowth of endometrial tissue due to unopposed estrogen, which can

How Crinone works in the body

Progesterone helps prepare the uterus for pregnancy. It works by activating a special protein, called Progesterone Receptor (PR), which is found in female reproductive tissue and the central nervous system. This protein helps control the growth and development of target tissues. Progesterone can also help prevent pregnancy by thickening cervical mucus and stopping ovulation. When taken perfectly, it has a failure rate of 0.5%. However, when taken regularly, the failure rate is estimated to be 5%.

When to interrupt dosage

The suggested dosage of Crinone is contingent upon the determined condition, such as hormonal imbalance, Female Infertility and Postmenopause. The amount of dosage is contingent upon the method of administration noted in the table beneath.

Condition

Dosage

Administration

recurrent spontaneous preterm birth

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Reproductive Technology

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Endometrial Hyperplasia

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Amenorrhea

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

hormonal imbalance

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Postmenopause

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Hysterectomy

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Amenorrhea

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Uterine hemorrhage

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Vasomotor System

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Hot flashes

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

prophylaxis of recurrent spontaneous preterm birth

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Warnings

Crinone Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thromboembolism

Do Not Combine

suspected pregnancy

Do Not Combine

Pulmonary Embolism

Do Not Combine

Stroke

Do Not Combine

Cerebrovascular accident

Do Not Combine

Thrombophlebitis

Do Not Combine

Breast

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Pulmonary Embolism

Do Not Combine

Pulmonary Embolism

Do Not Combine

Breast Cancer

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Breast

Do Not Combine

Breast

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

suspected pregnancy

Do Not Combine

Thromboembolism

Do Not Combine

Malignant Neoplasms

Do Not Combine

Stroke

Do Not Combine

undiagnosed vaginal bleeding

Do Not Combine

Abortion, Spontaneous

Do Not Combine

Venous Thrombosis

Do Not Combine

Thrombophlebitis

Do Not Combine

Stroke

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Progesterone may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Progesterone may interact with Pulse Frequency

There are 20 known major drug interactions with Crinone.

Common Crinone Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Progesterone.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Progesterone.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Progesterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Progesterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Progesterone.

Crinone Toxicity & Overdose Risk

The toxic dose of progesterone in rats is 327mg/kg. It is not recommended to use progesterone while pregnant and it may decrease fertility until it is stopped. Studies have found that progesterone may cause tumors in animals, but it is not yet known if this applies to humans. Using combined oral contraceptives has been linked to an increased risk of breast cancer, but it is not clear if progestin-only contraceptives have the same effect. Progesterone can be found in the milk of nursing mothers, but there have been no reports of negative effects on the baby. In rare cases, there have been reports

image of a doctor in a lab doing drug, clinical research

Crinone Novel Uses: Which Conditions Have a Clinical Trial Featuring Crinone?

Presently, there are 56 active clinical trials assessing the ability of Crinone Gel to aid Assisted Reproductive Techniques (ART) and Reproductive Technology.

Condition

Clinical Trials

Trial Phases

Endometrial Hyperplasia

0 Actively Recruiting

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

recurrent spontaneous preterm birth

0 Actively Recruiting

Uterine hemorrhage

0 Actively Recruiting

hormonal imbalance

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Amenorrhea

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Reproductive Technology

2 Actively Recruiting

Not Applicable

Amenorrhea

0 Actively Recruiting

prophylaxis of recurrent spontaneous preterm birth

0 Actively Recruiting

Hysterectomy

3 Actively Recruiting

Phase 3, Not Applicable

Crinone Reviews: What are patients saying about Crinone?

5

Patient Review

10/15/2007

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

4.3

Patient Review

3/13/2012

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I've been using this for a little over a week and have experienced fatigue and some breast tenderness. I also have mild cramping in my vaginal area, but it's not too bad. I'm unsure if it's okay to have intercourse while taking this drug because of the discharge.

4.3

Patient Review

5/24/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I had some uncomfortable side effects while taking this medication, including breast tenderness, cramping, heartburn and acne.

4

Patient Review

7/28/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I've had good results with this progesterone supplement, and it has far fewer side effects than other brands. The discharge can be a bit icky, and my breasts are sometimes sore, but that's it.

4

Patient Review

1/7/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

The side effects for me were really bad. I had headaches, was dizzy, and got cramps in my stomach.

3.7

Patient Review

5/30/2009

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I'm very drug sensitive, and this unfortunately did not work for me. The side effects weren't worth it either.

3

Patient Review

1/16/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I'm just starting out with this treatment, but I'm already seeing some positive results. My monthly cycles have become more regular, and I haven't experienced any terrible side effects. Just some minor headaches, breast tenderness, and discharge.

Patient Q&A Section about crinone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Crinone gel help implantation?

"The study found that the use of Crinone 8% vaginal progesterone gel was associated with a lower implantation rate than the use of IM progesterone-in-oil."

Answered by AI

What is the purpose of Crinone gel?

"This medication is used to treat infertility by increasing the levels of progesterone in the body. Progesterone is a hormone essential for maintaining pregnancy. This medication can also be used to restore menstrual cycles in women whose cycles have stopped."

Answered by AI

What is Crinone used for in IVF?

"Crinone is a medication used to treat infertility by providing extra progesterone. This is necessary when the body does not produce the correct levels of progesterone during the menstrual cycle, or when undergoing assisted fertility procedures. Crinone may also be used during pregnancy to support the new pregnancy."

Answered by AI

How long do you take Crinone during pregnancy?

"Crinone 8% is given vaginally as two 90 mg doses per day to women with partial or complete ovarian failure who need progesterone replacement. If pregnancy happens, treatment may continue until the placenta can function on its own, for up to 10 to 12 weeks."

Answered by AI

Clinical Trials for Crinone

Image of University of Texas in Houston, United States.

vNOTES Hysterectomy for Pelvic Prolapse

18+
Female
Houston, TX

As the adoption of Vaginal natural orifice transluminal endoscopic surgery (vNOTES) expands, attention is shifting from feasibility studies to the refinement of surgical steps that optimize long-term pelvic health. One technical distinction between vNOTES hysterectomy and conventional laparoscopic or robotic hysterectomy is the routine early transection of the uterosacral ligaments as the approach is caudal-cephalic. These ligaments are not merely anatomic landmarks-they are the primary apical support structures of the vagina, anchoring the vaginal cuff to the sacrum and providing resistance against downward displacement. Disruption of this support can predispose patients to apical vaginal prolapse, a condition that significantly affects quality of life and may require complex reconstructive surgery. Uterosacral ligament suspension (USLS) is a well-established, effective method of restoring apical support at the time of hysterectomy. Incorporating uterosacral suspension into vNOTES hysterectomy is a logical evolution toward ensuring that minimally invasive innovation does not come at the expense of long-term pelvic health. By adapting and standardizing this reconstructive step for vNOTES, surgeons can maintain apical support, reduce future prolapse risk, and uphold the same quality benchmarks established in laparoscopic and vaginal surgery. OBJECTIVE AND HYPOTHESIS: This study aims to present a practical, reproducible technique for performing USLS in the vNOTES setting and to evaluate its potential immediate benefits, possible complication rates, and additional operative time compared with vNOTES hysterectomy without USLS. In doing so, we seek to demonstrate that preventive pelvic support can be seamlessly integrated without compromising the efficiency or advantages of the transvaginal endoscopic approach.

Waitlist Available
Paid Trial

University of Texas

Image of Translational Physiology Laboratory within the Food Science Clinical Research Laboratory in Fort Collins, United States.

Mitoquinone for Postmenopausal Brain Health

18+
Female
Fort Collins, CO

The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team

Waitlist Available
Dietary Supplement

Translational Physiology Laboratory within the Food Science Clinical Research Laboratory

Have you considered Crinone clinical trials?

We made a collection of clinical trials featuring Crinone, we think they might fit your search criteria.
Go to Trials
Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Waitlist Available

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Crinone clinical trials?

We made a collection of clinical trials featuring Crinone, we think they might fit your search criteria.
Go to Trials
Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Have you considered Crinone clinical trials?

We made a collection of clinical trials featuring Crinone, we think they might fit your search criteria.
Go to Trials